Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 11/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286606 | 0.91 | PLAT (0.52) | PLATALDH1A1NPSR1HPGDHSD17B10 | |
| SCHEMBL15926261 | 0.89 | PLAT (0.49) | PLATALDH1A1NPSR1HPGDHSD17B10 | |
| SCHEMBL1614469 | 0.88 | PLAT (0.47) | PLATALDH1A1NPSR1HPGDHSD17B10 | |
| SCHEMBL1279373 | 0.82 | PLAT (0.59) | PLATALDH1A1NPSR1HPGDHSD17B10 | |
| SCHEMBL1278820 | 0.82 | PLAT (0.53) | PLATALDH1A1NPSR1HPGDHSD17B10 | |
| SCHEMBL1278767 | 0.80 | PLAT (0.47) | PLATALDH1A1NPSR1HPGDHSD17B10 | |
| SCHEMBL1286573 | 0.80 | PLAT (0.51) | PLATALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL1278684 | 0.79 | PLAT (0.56) | PLATALDH1A1NPSR1HPGDHSD17B10 | |
| SCHEMBL1286570 | 0.79 | PLAT (0.50) | PLATALDH1A1NPSR1HSD17B10KDM4E | |
| SCHEMBL1286584 | 0.79 | PLAT (0.56) | PLATALDH1A1NPSR1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796285-B2 | Pyrazolo [1,5-a]-pyrimidones derivatives and pharmaceutical compositions and uses thereof | HEBEI MEDICAL UNIVERSITY (CN) | 2014-08-05 | — | — | US | disclosed |
| US-8796285-B2 | Pyrazolo [1,5-a]-pyrimidones derivatives and pharmaceutical compositions and uses thereof | HEBEI MEDICAL UNIVERSITY (CN) | 2014-08-05 | — | — | US | disclosed |
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | PEKING UNIVERSITY (CN) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | KCNJ2, KCNQ5, KCNJ11 | PLAT 1286/4885ALDH1A1 159/4885NPSR1 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.